Overview

An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in

Status:
Completed

Trial end date:
2015-08-26

Target enrollment:

Participant gender:

Summary

The purpose of the study is to demonstrate the noninferiority of Algeron in combination with ribavirin compared to PegIntron in combination with ribavirin in treatment of chronic hepatitis C in Human Immunodeficiency Virus-1 infected patients

Phase:

Phase 3

Details

Lead Sponsor:

Biocad

Treatments:

Interferon-alpha
Peginterferon alfa-2b
Ribavirin